Table 1.
Demography and clinicopathological characteristics of patients included in the study.
| Variables | N (%) |
|---|---|
| Control | 5 (5.2) |
| Tumor | 91 (94.8) |
| Gender | |
| Male | 85 (88.5) |
| Female | 11 (11.5) |
| Age, yr, median ± SD (range) | 73 ± 10.48 (43–95) |
| Followup (median ± SD, range), in months | 46 ± 40.51 (2–125) |
| Molecular Subtypes | |
| Luminal | 65 (71.4) |
| Basal | 19 (20.9) |
| Null | 7 (7.7) |
| Histologic Subtype | |
| UC-conventional | 67 (73.6) |
| UC-with variant histology | 24 (26.4) |
| Clinical Subtypes | |
| NMIBC | 66 (72.5) |
| MIBC | 25 (27.5) |
| Tumor stage * | |
| Ta | 36 (39.5) |
| T1 | 30 (33.0) |
| T2-T4 | 25 (27.5) |
| Tumor Grade (WHO 2022) | |
| High-grade | 63 (69.2) |
| Low-grade | 28 (30.8) |
| PD-L1 expression | |
| High expression | 36 (40) |
| Low expression | 54 (60) |
| Risk categories ** | |
| Low | 14 (15.4) |
| Intermediate | 13 (14.3) |
| High | 38 (41.8) |
| Very High | 26 (28.6) |
| Recurrence event in NMIBC | |
| Yes | 36 (54.5) |
| No | 30 (45.5) |
| Progression event in NMIBC | |
| Yes | 7 (10.6) |
| No | 59 (89.4) |
| Survival (NMIBC and MIBC) | |
| NED | 34 (37.4) |
| AWD | 3 (3.3) |
| DBC | 26 (28.6) |
| DOC | 28 (30.7) |
* Stage category based on AJCC/TNM 2016 revision. ** Risk stratification system based on WHO 2004 grading. NED: No evidence of disease. AWD: Alive with disease. DBC: Died of bladder cancer. DOC: Dead of other causes.